{"entity":{"id":"nct07864701","kind":"trial","name":"Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers","aka":[],"tldr":"A phase 1/2 trial of JMBI-001 run by Chengdu Anticancer Bioscience, Ltd., now recruiting.","summary":"Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers is a phase 1/2 interventional study registered as NCT07864701 by Chengdu Anticancer Bioscience, Ltd., with 150 participants planned, started 2026-10. Conditions recorded: Advance Solid Tumors and Lymphoma, Non-Hodgkin. Interventions recorded: JMBI-001 Tablets.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07864701","url":"https://clinicaltrials.gov/study/NCT07864701"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["jmbi-001"],"companies":["anticancer-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07864701","phase":"1/2","setting":"A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity and Efficacy of JMBI-001 Tablets in Participants With MYC-Positive Advanced Solid Tumors or Relapsed/Refractory Non-Hodgkin Lymphoma","sponsor":"Chengdu Anticancer Bioscience, Ltd.","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07864701/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"jmbi-001","kind":"drug","name":"JMBI-001","route":"/drugs/jmbi-001/"}],"company":[{"id":"anticancer-bioscience","kind":"company","name":"Anticancer Bioscience","route":"/companies/anticancer-bioscience/"}]}}